Chief executive of the Pensions Board Brendan Kennedy, Minister for Social Protection Joan Burton TD and chairperson of the Pensions Board Jane Williams at the publication of the Pensions Board Annual Report and Accounts for 2012

Pensions Board chief says it is clear a number of schemes will close down

Elan chairman Robert Ingram at the company’s EGM in Dublin today. Photograph: Aidan Crawley

Outcome of special meeting in Dublin leaves sides effectively in stalemate

How do lower thresholds affect inheritance tax?

Elan has not confirmed the payment. Photograph: Bryan O’Brien

Company referred publicly to Jack Schuler as a ‘disgruntled director’

Elan chief executive Kelly Martin: the firm faces a critical moment in its volatile history with tomorrow’s EGM.

How the Irish biotech firm got to this point and how the EGM may play out

Elan chairman Robert Ingram. In a statement to the Irish Stock Exchange, Elan said it was “proceeding with a formal sale process”. Photograph: David Sleator

Review of proxies suggests stalemate after four-month battle for control of company

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday

Former Elan board member Jack Schuler has questioned the experience  of the drug company’s management. Photo: Bloomberg

Elan dismisses claims by Jack Schuler whom it calls ‘disgruntled’ as Royalty challenges Takeover Panel ruling

Royalty said it was concerned the takeover panel’s ruling would “deprive” Elan shareholders of the chance to consider its improved offer of $13 a share. Photographer: John Cogill/Bloomberg News

Deadline looms for vote of proxies in bitter battle

More articles

MARKETS

Facebook